Technologies Reshaping Biotherapeutics Manufacturing: An EU Perspective

By Staff Writer

September 15, 2023

The pharmaceutical landscape is ever-evolving, with innovative technologies continually reshaping the development, manufacture, and testing of biological medicinal products. However, these advancements also present regulatory challenges that need to be navigated for the benefit of patients.

Rapid Sterility Testing

Rapid sterility testing is a promising approach for cell and gene therapy products. However, it requires compliance with the Ph. Eur. 2.6.1 test for sterility, which is time-consuming due to the need for microbiological culture. Clearer regulatory guidance is needed to demonstrate that rapid sterility methods are suitable for their intended purposes and can meet the Ph. Eur. standards.

Multi-Attribute Methodologies

Multi-Attribute Methods (MAMs) by mass spectrometry offer the ability to test multiple quality attributes within a single method run. These methods generate rich data sets that can be retrospectively reassessed for new quality attributes. However, regulatory challenges exist, such as the lack of correlation between MAMs and conventional methods due to differences in the underlying measurement techniques.

Digitization and Artificial Intelligence

The use of modeling and digital twins represents an attractive approach for shortening the development times associated with standard CMC development. However, more thorough guidance is needed on real-time predictive modeling and how updates to the models fit the current EU variations legislation.

Continuous Manufacture

Despite the potential for increased process efficiency and reduced cost and time, end-to-end continuous manufacture (CM) has yet to be approved in an EU-licensed biologic product. One barrier to the implementation of CM for biomanufacturing is the time-to-result for in-process tests applied to critical process steps.

Conclusion

These are just some of the technologies reshaping biomanufacturing. It is crucial to ensure that EU assessors and inspectors are equipped with the skills, training, and relevant tools to regulate these new technologies. Furthermore, it is essential to communicate to the public that innovations in biomanufacturing, including artificial intelligence, do not result in lower quality medicines or negatively impact the safety and efficacy of medicines on the EU market.

Reference url

Recent Posts

Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidisciplinary Teams

By João L. Carapinha

September 1, 2025

Cardiovascular Business recently examines how closer collaboration cardiac surgery between interventional cardiologists and cardiac surgeons can increase patient referrals for surgical interventions. This is especially important as less-invasive procedures like transcatheter interventions grow in...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Eli Lilly is raising Mounjaro's UK price by 170% on September 1, 2025. The highest dose will jump from £122 to £330 monthly. But the company has negotiated discounts with pharmacies. This will lower the effective price to £247.50. This hike aims to align international pricing as it responds to pr...
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflammatory Diseases

By João L. Carapinha

August 30, 2025

MoonLake Immunotherapeutics HS, under the leadership of CEO Jorge Santos da Silva, is reimagining traditional biotech strategies with a concentrated approach to immunotherapeutic drug development. Utilizing innovative nanobody technology, the company is making strides in treating inflammatory dis...